Tulsian told CNBC-TV18, "I am not too convinced on Divi`s Labs particularly because firstly this has a very low tradability. So your impact cost is very high. Whenever you want to buy or sell, obviously impact costs are very high."
He further added, "If you make a comparative analysis, maybe stocks like Glenmark Pharma or maybe stocks like Biocon, Ranbaxy - they are looking better or maybe Aurobindo Pharma because the stock having corrected, probably I will look to make my buying list on those four stocks rather than Divi's Lab."
Anda sedang membaca artikel tentang
Prefer Glenmark Pharma, Biocon over Divis Lab: SP Tulsian
Dengan url
http://harmonisem.blogspot.com/2013/04/prefer-glenmark-pharma-biocon-over.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Prefer Glenmark Pharma, Biocon over Divis Lab: SP Tulsian
namun jangan lupa untuk meletakkan link
Prefer Glenmark Pharma, Biocon over Divis Lab: SP Tulsian
sebagai sumbernya
0 komentar:
Posting Komentar